Abstract:The small GTPase cycles between the inactive GDP form and the activated GTP form, catalyzed by the upstream guanine exchange factors. The modulation of such process by small molecules has been proven to be a fruitful route for therapeutic intervention to prevent the over-activation of the small GTPase. The fragment based approach emerging in the past decade has demonstrated its paramount potential in the discovery of inhibitors targeting such novel and challenging protein-protein interactions. The details regarding the procedure of NMR fragment screening from scratch have been rarely disclosed comprehensively, thus restricts its wider applications. To achieve a consistent screening applicable to a number of targets, we developed a highly automated protocol to cover every aspect of NMR fragment screening as possible, including the construction of small but diverse libray, determination of the aqueous solubility by NMR, grouping compounds with mutual dispersity to a cocktail, and the automated processing and visualization of the ligand based screening spectra. We exemplified our streamlined screening in RhoA alone and the complex of the small GTPase RhoA and its upstream guanine exchange factor LARG. Two hits were confirmed from the primary screening in cocktail and secondary screening over individual hits for LARG/RhoA complex, while one of them was also identified from the screening for RhoA alone. HSQC titration of the two hits over RhoA and LARG alone, respectively, identified one compound binding to RhoA.GDP at a 0.11 mM affinity, and perturbed the residues at the switch II region of RhoA. This hit blocked the formation of the LARG/RhoA complex, validated by the native gel electrophoresis, and the titration of RhoA to ¹⁵N labeled LARG in the absence and presence the compound, respectively. It therefore provides us a starting point toward a more potent inhibitor to RhoA activation catalyzed by LARG.

Iso-ADP-Ribose Fluorescence Polarization Probe for the Screening of RNF146 WWE Domain Inhibitors

Identification and Structure-Function Analyses of an Allosteric Inhibitor of the Tyrosine Phosphatase PTPN22.

Proteome-wide Analysis Reveals Substrates of E3 Ligase RNF146 Targeted for Degradation

A ligand discovery toolbox for the WWE domain family of human E3 ligases

Reversible phosphorylation of Rpn1 regulates 26S proteasome assembly and function

A genetically encoded sensor for real-time monitoring of poly-ADP-ribosylation dynamics in-vitro and in cells

Proteome-Wide Identification of poly(ADP-ribose) Binding Proteins

Activity-based probe profiling of RNF12 E3 ubiquitin ligase function in Tonne-Kalscheuer syndrome

A Genetically Encoded Sensor for Real-Time Monitoring of Poly-ADP-Ribosylation Dynamics In Vitro and in Cells

Concise machinery for monitoring ubiquitination activities using novel artificial RING fingers

RBR-type E3 Ubiquitin Ligase RNF144A Targets PARP1 for Ubiquitin-Dependent Degradation and Regulates PARP Inhibitor Sensitivity in Breast Cancer Cells.

Fluorescence polarization assay for screening FANCM-RMI inhibitors to target the alternative lengthening of telomeres

Automated NMR Fragment Based Screening Identified a Novel Interface Blocker to the LARG/RhoA Complex

Enabling Drug Discovery for the PARP Protein Family Through the Detection of Mono-Adp-ribosylation.

RNF166 promotes colorectal cancer progression by recognizing and destabilizing poly-ADP-ribosylated angiomotins

Target Fishing Reveals a Novel Mechanism of 1,2,4-Oxadiazole Derivatives Targeting Rpn6, a Subunit of 26S Proteasome

Cell-permeable nicotinamide adenine dinucleotides for exploration of cellular protein ADP-ribosylation

Development and characterization of new tools for detecting poly(ADP-ribose) in vitro and in vivo

A ribose-functionalized NAD+ with versatile activity for ADP-ribosylation

RNF114 suppresses tumour metastasis through the regulation of PARP10

High-throughput virtual screening to identify potential small molecule inhibitors of the Zα domain of the adenosine deaminases acting on RNA 1(ADAR1)